Extracted from this filing and checked against the source text.
Material Agreements
SEC 8-K Item 1.01/1.02
confidence 0.9
Aptose Biosciences Inc. entered into Registration Rights Agreement with Keystone Capital Partners, LLC (effective 2023-05-25).
- Action
- entry
- Counterparty
- Keystone Capital Partners, LLC
- Effective
- 2023-05-25
Exact text from the filing
Additionally, on May 25, 2023, the Company and Keystone entered into a registration rights agreement (the “ Registration Rights Agreement ”), pursuant to which the Company agreed to file a registration statement with the United States Securities and Exchange Commission (“ SEC ”) covering the resale of Common Shares that are issued to Keystone under the Purchase Agreement.
View on SEC.gov
Material Agreements
SEC 8-K Item 1.01/1.02
confidence 0.9
Aptose Biosciences Inc. entered into Purchase Agreement with Keystone Capital Partners, LLC valued at $25,000,000 (effective 2023-05-25).
- Action
- entry
- Agreement
- equity purchase
- Counterparty
- Keystone Capital Partners, LLC
- Value
- $25,000,000
- Effective
- 2023-05-25
Exact text from the filing
On May 25, 2023, Aptose Biosciences Inc. (the “ Company ”) and Keystone Capital Partners, LLC (“ Keystone ”), entered into a common share purchase agreement (the “ Purchase Agreement ”), which provides that subject to the terms and conditions set forth therein, the Company may sell to Keystone up to the lesser of (i) $25,000,000 of the Company’s common shares
View on SEC.gov